Breaking Finance News

ResMed Reports Positive Earnings

ResMed Inc. (NYSE: RMD) reports fiscal fourth quarter EPS of $0.62 versus consensus $0.61.  EPS were up 13 percent from the same quarter last year. Revenue came in at $414.60 million.

“We had many other accomplishments this quarter to report.  The Serve-HF heart failure trial is fully enrolled with over 1,325 patients.  In addition, we have finalized the protocol for our U.S. heart failure trial, CAT-HF and intend to begin enrollment this fall.  We introduced VPAP™ COPD, a first-of-its-kind respiratory product for those suffering from chronic obstructive pulmonary disease (COPD), and it is already doing well.  We launched the Quattro™ Air full face mask globally. This new mask is the lightest full face mask on the market, weighing in at just 3.3 ounces, making it 45 percent lighter than its predecessor and the current #1 seller in the U.S., the Mirage Quattro™. During the quarter, we also launched ResMed’s SleepSeeker – which is an online tool to increase patient engagement in therapy for sleep-disordered breathing.  With SleepSeeker, patients will be able to view their own therapy data, including time on therapy, any apnea or hypopnea events, and any mask leaks during the night.  Our aim is to improve therapy compliance through better patient engagement. These solutions will help in the management and control of various chronic diseases associated with both COPD and untreated sleep-disordered breathing.”

[stock-tools exchange="NYSE" symbol="RMD" image_height="230" image_width="350"]

Disclosure: At the time of this writing, the author had no position in the company mentioned.

New to Breaking Finance News? Read about our format here.

 

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.